• About us
    • About Lindahl
    • How we work
    • Said about Lindahl
    • Press
    • Find us
    • Privacy
  • Areas
    • Commercial dispute resolution
    • IT/Tech
    • Intellectual property
    • Life Sciences
    • M&A
    • All areas
  • Our people
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Helsingborg
    • Örebro
  • Latest news
    • Cases and transactions
    • News
    • Events
    • Knowledge
    • Portraits
  • Offices
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Örebro
    • Helsingborg

Lindahl advises NeuroVive in its directed share issue of MSEK 70

  • Home
  • Latest news
  • Cases and transactions
  • 2015
  • Lindahl advises NeuroVive in its directed share issue of MSEK 70

Advokatfirman Lindahl advises NeuroVive Pharmaceutical AB (publ), listed on Nasdaq Stockholm, in connection with its directed share issue. The share issue has been directed to a limited group of institutional qualified investors in the US through a private placement. The share volume and price per share have been determined through an accelerated bookbuilding process, where NeuroVive also has retained Chardan Capital Markets, LLC (US) as Lead Placement Agent and Sole Bookrunner, J. Streicher Capital, LLC (US) as Joint Lead Manager and HDR Partners AB as financial advisor. In total, NeuroVive has raised MSEK 70 through the issue before transaction costs.

A prospectus for the admission to trading of the shares issued in the new share issue is expected to be announced around 18 May 2015.

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases.

Advokatfirman Lindahl assists NeuroVive in the transaction through Annika Andersson (Capital Markets and Public M&A) with the assistance of Maria Arnoldsson (project manager, Capital Markets and Public M&A), Gabriela Baier-Sandén and Sebastian Iso-Kamula (Capital Markets and public M&A), Jonas Löfgren (Life Science), Annie Kabala (Life Science/Intellectual Property) and Anna Romell Stenmark (Tax).

Contact

  • Anna Romell Stenmark

    Uppsala

    anna.romell.stenmark@lindahl.se +46 705 261 863
Pages
  • Start
  • About us
  • Areas
  • Our people
  • Latest news
  • Privacy
Our offices
  • Stockholm reception.stockholm@lindahl.se +46 8 527 70 800
  • Göteborg reception.goteborg@lindahl.se +46 31 799 10 00
  • Malmö reception.malmo@lindahl.se +46 40 664 66 50
  • Uppsala reception.uppsala@lindahl.se +46 18 16 18 50
  • Örebro reception.orebro@lindahl.se +46 19 20 89 00
  • Helsingborg reception.helsingborg@lindahl.se +46 42 17 53 00
Social media
  • Connect with us on social networks: Instagram, Linkedin, Youtube, Facebook,

Disclaimer

The material and information on this site is intended for general informational purposes only and does not constitute legal advice on any specific matter. Please note that all images on Lindahl's website, www.lindahl.se, are subject to intellectual property protection and downloading, publication, copying and/or other use of the images requires the written consent of the rights holder. You'll find Advokatfirman Lindahl KB's general terms and conditions here.

Some cookies are essential, others help us improve your experience by providing insights into how the site is used. For more information, please visit our Cookie Policy.

Essential Cookies

These cookies are necessary for the functionality of the site and cannot be disabled.

Analytics Cookies>

We use Analytics cookies to collect information that gives us insight into how our website is being used. We anonymize IP addresses in Google Analytics. By clicking on Decline we won't save theese cookies.

Decline
We use cookies to get insights on how our site is used and give our visitors the best possible experience